Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed distinct post-marketing safety signal patterns for baricitinib and tofacitinib in adult AA, influenced by their differing regulatory uses and real-world contexts, and emphasizes the need for future studies to validate these findings.

This case report presents three sisters with familial frontal fibrosing alopecia, making it the 25th documented familial case, with treatment results observed in one sister.

This study identified that trichoscopy can effectively diagnose frontal fibrosing alopecia by highlighting specific scalp abnormalities in postmenopausal women.

This study demonstrated that Forsythiaside A improved survival and reduced neurological deficits in rats with cerebral ischemic injury, potentially through activating Nrf2 and reducing ER stress pathways.

This study reported that frontal fibrosing alopecia predominantly affects postmenopausal women and identified potential risk factors like frequent β-blocker use and sunscreen application, indicating the need for further research.

This study observed that some children and young adults with alopecia areata experienced flares during long-term tofacitinib treatment, despite initial successful hair regrowth.

This case report describes a novel instance of scarring alopecia with features of frontal fibrosing alopecia in a patient with systemic sclerosis, suggesting a potential link between the two conditions not previously reported.

This study found that a novel pet food formulation significantly improved the management of feline atopic skin syndrome by reducing symptom severity and medication dependence over six months in client-owned cats, compared to a control diet.

This article discusses current methods in facial feminization surgery for transsexual women and reports no new clinical results, focusing instead on various surgical techniques used to feminize facial features.

This study observed an alopecia syphilitica-like pattern of hair loss in a woman with frontal fibrosing alopecia, suggesting it may be another atypical presentation of the condition.

The researchers in this study identified molecular mechanisms involved in frontal fibrosis alopecia, highlighting immune response and fatty acid metabolism, and developed a four-gene diagnostic model showing high accuracy in distinguishing affected individuals from controls.

This paper presents consensus guidelines for standardized diagnostic criteria and assessment methods for frontal fibrosing alopecia to improve clinical research and data collection globally.

Tofacitinib may effectively treat folliculitis decalvans.

This case report describes a 46-year-old man diagnosed with frontal fibrosing alopecia, a condition primarily affecting postmenopausal women, highlighting its rare occurrence in men.

This study found that oral tofacitinib achieved significant hair regrowth in children with moderate to severe alopecia areata, with 72.2% reaching a 75% improvement and 52.8% achieving complete regrowth, though some patients did not respond and further research is needed on the treatment's long-term effects.

This study found that tofacitinib was an effective and well-tolerated treatment for alopecia areata, with significant to moderate hair regrowth in 78% of patients observed.

The Fas/FasL pathway may play a role in alopecia areata.

This abstract describes frontal fibrosing alopecia, a type of cicatricial alopecia identified in post-menopausal women, and reports no new clinical findings.

This review highlights that Tremella fuciformis polysaccharide exhibits various bioactivities, such as antioxidant and immune-modulating effects, and explores its potential applications in food, pharmaceutical, and cosmetic industries.

This study found that tofacitinib was well tolerated and led to clinical improvement in 77% of potential responders with severe alopecia areata, alopecia totalis, or alopecia universalis.

Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.

This review summarizes findings on the long-term use of tofacitinib for severe alopecia areata, reporting its potential as a promising treatment option.

This review discusses the evolving understanding of frontal fibrosing alopecia as a generalized skin condition with diverse manifestations, and reports no new clinical results.

Topical tofacitinib helped a man with severe scalp condition after other treatments failed.

This review article examines the current understanding of frontal fibrosing alopecia, noting its prevalence in different demographics and the roles of genetic and environmental factors in its pathogenesis, while highlighting that treatment approaches remain varied and lack standardization.

This chapter reviews trichoscopic-pathologic correlations in Frontal Fibrosing Alopecia and reports no new clinical results; the authors discuss genetics, clinical patterns, and unusual variants associated with this condition.

This study suggests the existence of a new subtype of alopecia, called 'acute diffuse and total alopecia of the female scalp (ADTAFS)', characterized by acute, diffuse hair loss primarily in women and a rapid recovery.

This meta-analysis suggests a significant association between the use of facial sunscreen and moisturizer and frontal fibrosing alopecia, while finding no significant relationship with hair products or treatments.

This study reports a case of traumatic anserine folliculosis in a young male, where treatment with topical retinoids and keratolytics combined with avoiding friction significantly improved symptoms after nine months.

This study found that tofacitinib is an effective and more tolerable treatment than systemic corticosteroids for moderate-to-severe alopecia areata, and its combination with corticosteroids may offer improved efficacy.